Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Avrobio Inc
(NQ:
AVRO
)
1.400
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Avrobio Inc
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
May 18, 2023
Via
Benzinga
Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months
May 18, 2023
Avrobio Inc (NASDAQ: AVRO) announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of an investigational gene therapy for...
Via
Benzinga
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting
May 18, 2023
From
AVROBIO, Inc.
Via
Business Wire
Recap: Avrobio Q1 Earnings
May 11, 2023
Via
Benzinga
AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
From
AVROBIO, Inc.
Via
Business Wire
Avrobio Touts New Positive Data From Gaucher Disease Gene Therapy
December 07, 2022
Via
Benzinga
AVROBIO Announces Leadership Transition
May 01, 2023
From
AVROBIO, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
March 23, 2023
Via
Benzinga
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
March 23, 2023
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference
March 03, 2023
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023
February 09, 2023
From
AVROBIO, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 10, 2023
Via
Benzinga
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2023
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Clinical Data For Gaucher Disease Gene Therapy; Says 'Following positive feedback from FDA and MHRA, registrational, global Phase 2/3 clinical trial for GD3 planned for second half 2023'
December 07, 2022
New compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gaucher disease type 1 (GD1) patients dosed with investigational AVR-RD-02 Data from first pediatric GD3...
Via
Benzinga
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
December 07, 2022
From
AVROBIO, Inc.
Via
Business Wire
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
November 29, 2022
Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group,
Via
Benzinga
AVROBIO to Share Comprehensive Gaucher Disease Program Update
November 17, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit
November 07, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
October 27, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis
October 25, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
October 18, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development
October 11, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 06, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
September 27, 2022
From
AVROBIO, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 20, 2022
Via
Benzinga
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
September 20, 2022
As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a...
Via
Benzinga
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis
September 20, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial
September 14, 2022
From
AVROBIO, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.